Up to now only acetylcholine esterase inhibitors, such as neostigmine, were available as antagonists of residual neuromuscular blocks. Sugammadex is a modified gamma-cyclodextrin that binds rocuronium and chemically similar aminosteroidal muscle relaxants, such as vecuronium. The underlying mechanism of action is new and differs completely from that of acetylcholine esterase inhibitors. This review summarizes data published so far within the framework of the licensing procedure about the efficacy, safety and side-effects of sugammadex and presents potential new anesthesiological concepts using this compound
Abstract Sugammadex, a modified gamma-cyclodextrin, has changed clinical practice of neuromuscular r...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Sugammadex is a modified gamma-cyclodextrin that acts by selectively encapsulating free amino-steroi...
Contains fulltext : 79739.pdf (publisher's version ) (Closed access)Up to now only...
Contains fulltext : 81109.pdf (publisher's version ) (Closed access)Sugammadex is ...
Sugammadex is a modified cyclodextrin which acts by encapsulating and inactivating the neuromuscular...
Since its first human use in 2005, the γ-cyclodextrin sugammadex (Org 25969) has had the potential t...
Postoperative residual curarization is still a problem of the modern anesthesia. Neostigmine is not ...
Sugammadex, a gamma cyclodextrin discovered in 2007, provides a safe and effective alternative to dr...
Neuromuscular blocking agents are a substantial element of anaesthesia in almost every surgical fiel...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
An ideal reversal agent could be given at any time after the administration of a neuromuscular block...
Residual paralysis, with its subsequent postoperative pulmonary sequelae, is one of the major compli...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
Abstract Sugammadex, a modified gamma-cyclodextrin, has changed clinical practice of neuromuscular r...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Sugammadex is a modified gamma-cyclodextrin that acts by selectively encapsulating free amino-steroi...
Contains fulltext : 79739.pdf (publisher's version ) (Closed access)Up to now only...
Contains fulltext : 81109.pdf (publisher's version ) (Closed access)Sugammadex is ...
Sugammadex is a modified cyclodextrin which acts by encapsulating and inactivating the neuromuscular...
Since its first human use in 2005, the γ-cyclodextrin sugammadex (Org 25969) has had the potential t...
Postoperative residual curarization is still a problem of the modern anesthesia. Neostigmine is not ...
Sugammadex, a gamma cyclodextrin discovered in 2007, provides a safe and effective alternative to dr...
Neuromuscular blocking agents are a substantial element of anaesthesia in almost every surgical fiel...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
An ideal reversal agent could be given at any time after the administration of a neuromuscular block...
Residual paralysis, with its subsequent postoperative pulmonary sequelae, is one of the major compli...
Sugammadex is the first selective relaxant binding agent. It allows rapid reversal of any degree of ...
Abstract Sugammadex, a modified gamma-cyclodextrin, has changed clinical practice of neuromuscular r...
peer reviewedBackground: Sugammadex rapidly reverses rocuronium-induced neuromuscular block. This st...
Sugammadex is a modified gamma-cyclodextrin that acts by selectively encapsulating free amino-steroi...